Enclomiphene Citrate Hair and Skin Changes: What the Clinical Evidence Shows

What Enclomiphene Studies Actually Measured

Published randomized studies evaluated enclomiphene in men with secondary hypogonadism. They found increases in endogenous testosterone, luteinizing hormone, and follicle-stimulating hormone, with preservation of sperm counts compared with topical testosterone.[1][2][3]

These studies are important for fertility and hormone outcomes. They do not establish a rate of male-pattern hair loss, acne, skin oiliness, collagen improvement, or wound-healing benefit. A page about hair and skin therefore has to distinguish direct evidence from biological inference.

Could Enclomiphene Affect Scalp Hair?

It is plausible, but not quantified.

Androgens act differently at different hair follicles. In genetically susceptible scalp follicles, androgen signaling—particularly involving dihydrotestosterone—contributes to androgenetic alopecia.[4] If enclomiphene raises testosterone, the amount available for conversion to dihydrotestosterone can also change. That does not mean enclomiphene directly damages follicles or that every testosterone increase produces visible loss.

Published enclomiphene trials do not provide a validated timeline, a dose-response curve for hair loss, or a serum DHT cutoff that predicts shedding. Claims that hair loss should begin at a specific week or that DHT above a particular number requires treatment are not supported by enclomiphene-specific evidence.

Could It Cause Acne or Oily Skin?

An androgen change can plausibly influence sebaceous glands and acne in a susceptible person. The enclomiphene studies, however, were not acne trials and do not supply a reliable acne-incidence percentage.

It is not sound to borrow a percentage from a testosterone-gel trial and present it as enclomiphene's rate. The route of administration, hormone dynamics, participants, and adverse-event collection differ.

If acne begins or worsens after treatment starts, useful observations include:

• the timing relative to starting or changing the dose;
• whether acne was present before treatment;
• the body areas affected;
• other medicines or supplements;
• measured hormone changes; and
• whether symptoms change when the prescribing plan changes.

The 2024 acne guideline provides evidence-based treatment options according to acne severity, but it does not contain an enclomiphene-specific acne protocol.[5]

What Is Not Established

Current published evidence does not establish that enclomiphene:

• improves skin collagen or elasticity;
• accelerates wound healing in humans;
• is better or worse for skin than racemic clomiphene;
• causes a predictable 4-to-12-week acne or shedding sequence;
• requires preventive finasteride;
• should be paired with a specific topical regimen; or
• can be managed using a universal DHT target.

Those claims may sound mechanistically plausible, but plausibility is not a clinical outcome study.

A Practical Evaluation Plan

Before treatment, it can be useful to document existing acne and the scalp hairline, particularly when there is already androgenetic alopecia. If a change appears, compare photographs taken with similar lighting and angle rather than relying on day-to-day shedding counts.

Discuss persistent acne, scalp thinning, breast symptoms, mood changes, visual symptoms, or other new effects with the prescriber. The clinician can review whether the hormone response, dose, diagnosis, or treatment itself needs reassessment.

Do not automatically add finasteride or dutasteride. Finasteride has evidence for male androgenetic alopecia,[6] but it also has its own indications, contraindications, and adverse effects. Evidence for finasteride does not prove that every person using enclomiphene should receive it.

Compounded Enclomiphene and Product Quality

There is no FDA-approved enclomiphene drug product. A compounded product is not FDA approved, and FDA does not verify its safety, effectiveness, or quality before marketing in the way it does for an approved drug. This does not erase the clinical research on the molecule, but it means evidence from a studied formulation should not be assumed to prove the content or performance of every compounded preparation.[7]

Patients should use a licensed prescriber and a properly licensed pharmacy and should know exactly what formulation and strength they received.

The Bottom Line

Enclomiphene raises endogenous reproductive hormones in published trials. Hair loss and acne are plausible concerns when androgen exposure changes, but their enclomiphene-specific frequency, timing, and predictors are unknown.

The most accurate approach is to document baseline hair and skin, monitor actual changes, and make treatment decisions with the prescriber. Fixed DHT thresholds, automatic finasteride co-treatment, and precise acne or shedding timelines go beyond the available evidence.